EPA Approves New, Broader Pathogen Killing Claims for Applied Silver’s SilvaClean® Commercial Laundry Additive Now Used in Healthcare and Sports Medicine Programs
March 28, 2019 13:19 ET
|
Applied Silver Inc.
EPA Agrees SilvaClean® Kills MRSA and a Broad Range of Antibiotic-Resistant Pathogens Company Appoints Mark Neaman, former Chairman, President and CEO of NorthShore (IL) University Health Systemto...
Applied Silver Announces Formation of Athlete Advisory Council with the Appointment of Ian Williams, Former San Francisco 49ers Player, as Athletics Ambassador
March 13, 2019 07:00 ET
|
Applied Silver Inc.
HAYWARD, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Applied Silver, Inc. today announced the appointment of Ian Williams, former San Francisco 49ers defensive lineman and NBC Bay Area Sports Analyst...
IHMA Announces a New Venture in India to Further Their Global Support of Anti-infective Drug Development for the Biopharmaceutical Industry
October 31, 2018 17:22 ET
|
IHMA Inc
SCHAUMBURG, Ill., Oct. 31, 2018 (GLOBE NEWSWIRE) -- International Health Management Associates, Inc./IHMA Europe Sàrl (IHMA), a global company that provides laboratory and consultative services to...
First Choice Bancorp Congratulates FIGS, Inc. for Receiving the Ernst & Young Entrepreneur Year® 2018 award for Emerging Entrepreneur
July 09, 2018 09:00 ET
|
First Choice Bancorp
CERRITOS, CALIFORNIA, July 09, 2018 (GLOBE NEWSWIRE) -- (Nasdaq Capital Markets: FCBP) - First Choice Bancorp, the holding company for First Choice Bank (the “Bank”), congratulates Heather Hasson,...
IHMA Completes the Globalization of its Two Laboratories with the Recent College of American Pathologists (CAP) Accreditation of IHMA Europe, Enhancing Support for Clinical Trials in Anti-Infective Drug Development and Global Surveillance Studies
March 06, 2018 17:20 ET
|
IHMA Inc
SCHAUMBURG, Ill., March 06, 2018 (GLOBE NEWSWIRE) -- On 14th October 2017 IHMA Europe Sàrl, located in Monthey, Valais, Switzerland, was awarded accreditation by the College of American Pathologists...
Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd
December 23, 2017 16:00 ET
|
Summit Therapeutics plc
Positions Summit as a Leader in Research & Development of New Classes of AntibioticsEnhances Summit’s Broader Business in Rare and Infectious DiseasesSupports Mission to Discover and Develop...
NTS Ventures and IHMA Announce a Collaborative Agreement to Provide an Extensive Suite of Clinical Mycology, Antifungal and Microbiology Laboratory Services to Support Anti-infective Drug Development to the Biopharmaceutical Industry
December 04, 2017 17:24 ET
|
IHMA Inc
SCHAUMBURG, Ill., Dec. 04, 2017 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl...
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
October 09, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 09, 2017 16:31 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics to Host Investor Day on April 6, 2017
March 29, 2017 07:30 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, March 29, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day...